Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 80 pages | ID: D5DFD09CFA82EN
Global Markets Direct

Abstracts

Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), light-headedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 4, 2, 1, 10 and 13 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dilated Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Avery Therapeutics Inc
Berlin Cures Holding AG
BioMarin Pharmaceutical Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Cardior Pharmaceuticals GmbH
Celixir Ltd
CellServe GmbH
DiNAQOR AG
Dynomics Inc
Heartseed Inc
Help Therapeutics
iHeart Japan Corp
Martin Pharmaceuticals Inc
Maze Therapeutics Inc
NeoProgen Inc
Nuevocor Pte Ltd
Olagenesis Corp
Pfizer Inc
Recursion Pharmaceuticals Inc
Renovacor Inc
Shionogi & Co Ltd
Tenaya Therapeutics Inc
Dilated Cardiomyopathy - Drug Profiles
BC-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDR-426D - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
danicamtiv - Drug Profile
Product Description
Mechanism Of Action
History of Events
DINA-005 - Drug Profile
Product Description
Mechanism Of Action
DINA-006 - Drug Profile
Product Description
Mechanism Of Action
DINA-008 - Drug Profile
Product Description
Mechanism Of Action
DINA-009 - Drug Profile
Product Description
Mechanism Of Action
DINA-010 - Drug Profile
Product Description
Mechanism Of Action
DINA-011 - Drug Profile
Product Description
Mechanism Of Action
DYN-101 - Drug Profile
Product Description
Mechanism Of Action
emprumapimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Dilated Cardiomyopathy and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Heartcel - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IHJ-301 - Drug Profile
Product Description
Mechanism Of Action
MyCardia - Drug Profile
Product Description
Mechanism Of Action
Neo-2001 - Drug Profile
Product Description
Mechanism Of Action
NovoCardia - Drug Profile
Product Description
Mechanism Of Action
redasemtide trifluoroacetate - Drug Profile
Product Description
Mechanism Of Action
REN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
TN-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
History of Events
YS-1402 - Drug Profile
Product Description
Mechanism Of Action
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021
Sep 09, 2020: MyoKardia doses first patient in phase 2 clinical trial of danicamtiv in genetic dilated cardiomyopathy
Mar 26, 2020: MyoKardia Provides clinical trial update on Danicamtiv study
Oct 28, 2019: MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
May 30, 2019: MyoKardia’s MYK-491 shows favourable profile in Phase Ia study
Apr 15, 2019: Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of ?1-adrenoceptor autoantibodies
Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients
Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC
Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day
Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Nov 02, 2017: MyoKardia Provides Update on MYK-491
Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Dilated Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dilated Cardiomyopathy - Pipeline by Avery Therapeutics Inc, 2022
Dilated Cardiomyopathy - Pipeline by Berlin Cures Holding AG, 2022
Dilated Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2022
Dilated Cardiomyopathy - Pipeline by BridgeBio Pharma Inc, 2022
Dilated Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2022
Dilated Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2022
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, 2022
Dilated Cardiomyopathy - Pipeline by CellServe GmbH, 2022
Dilated Cardiomyopathy - Pipeline by DiNAQOR AG, 2022
Dilated Cardiomyopathy - Pipeline by Dynomics Inc, 2022
Dilated Cardiomyopathy - Pipeline by Heartseed Inc, 2022
Dilated Cardiomyopathy - Pipeline by Help Therapeutics, 2022
Dilated Cardiomyopathy - Pipeline by iHeart Japan Corp, 2022
Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, 2022
Dilated Cardiomyopathy - Pipeline by Maze Therapeutics Inc, 2022
Dilated Cardiomyopathy - Pipeline by NeoProgen Inc, 2022
Dilated Cardiomyopathy - Pipeline by Nuevocor Pte Ltd, 2022
Dilated Cardiomyopathy - Pipeline by Olagenesis Corp, 2022
Dilated Cardiomyopathy - Pipeline by Pfizer Inc, 2022
Dilated Cardiomyopathy - Pipeline by Recursion Pharmaceuticals Inc, 2022
Dilated Cardiomyopathy - Pipeline by Renovacor Inc, 2022
Dilated Cardiomyopathy - Pipeline by Shionogi & Co Ltd, 2022
Dilated Cardiomyopathy - Pipeline by Tenaya Therapeutics Inc, 2022
Dilated Cardiomyopathy - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dilated Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022